Autopsy report · NCT01391117

TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin

“Antiviral activity was considered insufficient to warrant further clinical development of TMC649128.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 months before it stopped.
• 14 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Tibotec BVBA

Sponsor type

Industry

Conditions

Hepatitis C Virus

Interventions

placebo.; placebo.; TMC649128.; placebo.; placebo; TMC649128

Participants

14

Sites

3

Countries

Netherlands, Poland

Trials that died the same way

• First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
  “ALS-2158 showed insufficient antiviral activity to warrant proceeding with further clinical development.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.